抗BCMA CAR T细胞疗法bb2121治疗复发或难治性多发性骨髓瘤
这项1期研究纳入既往接受过至少三线治疗(含蛋白酶体抑制剂和免疫调节剂)或对两类药物均难治的复发或难治性多发性骨髓瘤患者,单次输注bb2121。33例可评估患者中客观缓解率为85%,45%达完全缓解,中位无进展生存期为11.8个月;细胞因子释放综合征发生率为76%,神经系统毒性发生率为42%。
要点
- bb2121单次输注在复发或难治性多发性骨髓瘤中客观缓解率为85%,45%达完全缓解。
- 3级及以上血液学毒性常见:中性粒细胞减少85%、白细胞减少58%、贫血45%、血小板减少45%。
- 细胞因子释放综合征发生率为76%,其中3级为6%;神经系统毒性发生率为42%。
核心结论
- 报告了靶向BCMA的细胞免疫疗法在复发或难治性多发性骨髓瘤患者中的初步毒性特征,并记录了抗肿瘤活性。
研究设计与样本
- 1期研究,剂量递增阶段单次输注50×10^6、150×10^6、450×10^6或800×10^6 CAR阳性T细胞,扩展阶段输注150×10^6至450×10^6 CAR阳性T细胞。
- 患者既往接受过至少三线治疗,包括蛋白酶体抑制剂和免疫调节剂,或对这两类药物均难治。
- 主要终点为安全性;报告了首批连续33例接受bb2121输注患者的结果,数据截止日期为末次输注日期后6.2个月。
主要发现
- 3级或以上血液学毒性:中性粒细胞减少85%、白细胞减少58%、贫血45%、血小板减少45%。
- 25例(76%)发生细胞因子释放综合征,其中1或2级23例(70%),3级2例(6%)。
- 14例(42%)发生神经系统毒性,其中1或2级13例(39%);1例(3%)发生可逆的4级神经系统毒性。
- 客观缓解率为85%,包括15例(45%)完全缓解;15例完全缓解患者中6例复发。
- 中位无进展生存期为11.8个月(95%CI 6.2至17.8);16例可评估微小残留病灶的缓解患者(部分缓解或更好)均为MRD阴性(≤10^-4个有核细胞)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS: In this phase 1 study involving patients with relapsed or refractory multiple myeloma, we administered bb2121 as a single infusion at doses of 50×106, 150×106, 450×106, or 800×106 CAR-positive (CAR+) T cells in the dose-escalation phase and 150×106 to 450×106 CAR+ T cells in the expansion phase. Patients had received at least three previous lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or were refractory to both drug classes. The primary end point was safety. RESULTS: Results for the first 33 consecutive patients who received a bb2121 infusion are reported. The data-cutoff date was 6.2 months after the last infusion date. Hematologic toxic effects were the most common events of grade 3 or higher, including neutropenia (in 85% of the patients), leukopenia (in 58%), anemia (in 45%), and thrombocytopenia (in 45%). A total of 25 patients (76%) had cytokine release syndrome, which was of grade 1 or 2 in 23 patients (70%) and grade 3 in 2 patients (6%). Neurologic toxic effects occurred in 14 patients (42%) and were of grade 1 or 2 in 13 patients (39%). One patient (3%) had a reversible grade 4 neurologic toxic effect. The objective response rate was 85%, including 15 patients (45%) with complete responses. Six of the 15 patients who had a complete response have had a relapse. The median progression-free survival was 11.8 months (95% confidence interval, 6.2 to 17.8). All 16 patients who had a response (partial response or better) and who could be evaluated for minimal residual disease (MRD) had MRD-negative status (≤10-4 nucleated cells). CAR T-cell expansion was associated with responses, and CAR T cells persisted up to 1 year after the infusion. CONCLUSIONS: We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented. (Funded by Bluebird Bio and Celgene; CRB-401 ClinicalTrials.gov number, NCT02658929.).
引用
- Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019. PMID: 31042825. doi:10.1056/NEJMoa1817226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。